The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Barriers to implementing of ctDNA approaches into clinical practice for patients with colon cancer
Jonathan Nowak, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the challenges of obtaining specimens for tumor agnostic approaches in colorectal cancer, highlighting the need for matched tumor tissue and normal tissue, as well as plasma samples, to enable sensitive testing. Dr Nowak emphasizes the importance of actionable information that can inform treatment decisions, such as the use of NSAIDs or celecoxib, and notes that more evidence is needed to demonstrate the predictive value of ctDNA positivity in altering treatment suggestions. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
